Is it Time to Bet on Canada’s Cannabis Giants?

Should you buy Aurora Cannabis (TSX:ACB) stock and Canopy Growth (TSX:WEED) stock right now?

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

A few cannabis stocks made a strong comeback in May 2020. This consistent upward surge in the last month has garnered investor attention. Does this mean pot stocks are poised to move higher in the second half of 2020 and crush market returns? Or is the recent uptick a temporary recovery?

Let’s see if the time is ripe to invest in Canada’s marijuana giants such as Aurora Cannabis (TSX:ACB)(NYSE:ACB) and Canopy Growth (TSX:WEED)(NYSE:CGC).

Aurora Cannabis stock is up 150% in the last month

Shares of Aurora Cannabis are trading at $19, which is 150% higher than its 52-week low of $7.5. It gained momentum on the back of better-than-expected fiscal third-quarter results. Aurora Cannabis announced its Q3 results on May 15 and reported net revenue of $78.4 million, a sequential growth of 18%.

Aurora’s revenue was above analyst revenue estimates of $66.7 million, driven by recreational and medical marijuana sales. Aurora also announced its acquisition of Reliva, a top-selling cannabidiol (CBD) brand, providing the former with a way to enter the U.S. CBD market.

This acquisition deal is expected to close this month and will help Aurora improve profitability. The news cheered investors due to Aurora’ less than impressive profit margins and cash burn.

Canopy Growth announced Q4 results

Another marijuana leader, Canopy Growth announced its quarterly results in May. It reported revenue of $107.9 million, well below estimates of $128.9 million. Canopy’s sales were up 15% year-over-year but fell 13% on a sequential basis. Further, it posted a net loss of a staggering $1.3 billion or $3.72 per share.

The net loss was primarily driven by impairment and restructuring charges of $743 million. Canopy’s selling, general and administrative costs rose 17% sequentially as well which further impacted the bottom line.

Canopy depends on business-to-business sales of adult-use marijuana products for revenue growth. In Q4, B2B sales were down 31% sequentially at $36.7 million. As retail stores were closed, its business-to-consumer sales declined 14% from Q3 to $13.1 million.

Canopy’s less than impressive Q4 results drove the stock lower. Shares are currently trading at $22.4 which is close to 70% below its record highs.

Why are cannabis stocks not out of the woods?

Cannabis stocks have burnt significant investor wealth in the last 15 months for several reasons. While the total addressable market continues to expand at a rapid pace, there are a lot of uncertainties for investors.

Over the last few years, Aurora, Canopy, and peers paid a premium to acquire companies. This overvaluation is coming back to haunt them, resulting in massive write-downs and goodwill impairments. Aurora Cannabis still has $2.42 billion in goodwill that accounts for 51% of its total assets.

These acquisitions have also had an impact on the cash reserves of Aurora Cannabis. The pot leader had to raise equity capital, which has diluted shareholder wealth considerably.

The Foolish takeaway

Aurora Cannabis and Canopy Growth are two stocks that still seem a risky buy at their current levels. Their mounting losses and a tepid demand environment make them unattractive to investors. Though cannabis stocks are high-risk they will also reward investors if the market manages to rebound.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »